TY - JOUR
T1 - Keeping the blood flowing
T2 - New agents to prevent and treat thrombosis
AU - Fitzmaurice, D.
N1 - Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/10/1
Y1 - 2011/10/1
N2 - We live in exciting times with the development of several new oral anticoagulant agents, including the recent approval of the direct thrombin inhibitor dabigatran for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). Dabigatran, an oral agent with fixed dosing, is an attractive alternative to warfarin which has recently been made available in the UK. What are the implications for UK primary care? Many patients with AF receive substandard anticoagulation and are therefore at risk of stroke. Evidence for its efficacy and its potential place in clinical practice is reviewed.
AB - We live in exciting times with the development of several new oral anticoagulant agents, including the recent approval of the direct thrombin inhibitor dabigatran for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). Dabigatran, an oral agent with fixed dosing, is an attractive alternative to warfarin which has recently been made available in the UK. What are the implications for UK primary care? Many patients with AF receive substandard anticoagulation and are therefore at risk of stroke. Evidence for its efficacy and its potential place in clinical practice is reviewed.
UR - http://www.scopus.com/inward/record.url?partnerID=yv4JPVwI&eid=2-s2.0-82855166091&md5=b2d2e283c5afd1f7055cfe0276d2a18d
U2 - 10.3132/pccj.2011.066
DO - 10.3132/pccj.2011.066
M3 - Article
AN - SCOPUS:82855166091
SN - 1756-5138
VL - 4
SP - 147
EP - 148
JO - Primary Care Cardiovascular Journal (PCCJ)
JF - Primary Care Cardiovascular Journal (PCCJ)
IS - 4
ER -